上述数据使用的会计准则为 NonUS_GAAP。$Calliditas Therapeutics (CALT.US)$The financial report will be released on November 11th, investors are welcome to pay attention.
How was the previous performance?
$Calliditas Therapeutics (CALT.US)$In Q2 2024, revenue was 0.55978 billion kronor, net income was -47.478 million kronor, with an EPS of -1.76 kronor.
In Q3 2023, revenue was 0.294592 billion kronor, net income was -0.168357 billion kronor, with an EPS of -6.28 kronor.
The accounting standards used in the above data are NonUS_GAAP.
Futubull reminder:
1. There is no strict requirement for the division of accounting year for Hong Kong and US listed companies, which is entirely determined by the company itself. Therefore, each financial reporting period can be used as the company's annual report deadline, rather than using the calendar year as the fiscal year.
2. Generally, the company will hold a financial report conference on the above financial report release date or nearby dates. At that time, the company's management will discuss and explain the latest quarterly financial data and operational situation, and communicate with investors, analysts, media, etc.
Investors can participate through offline meetings or online teleconferences, etc.
